NASDAQ:APVO
Aptevo Therapeutics Inc Stock News
$0.711
-0.0189 (-2.59%)
At Close: May 24, 2024
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
09:00am, Friday, 09'th Apr 2021
SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its propriet
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
08:00am, Wednesday, 31'st Mar 2021
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up
An Assessment On Aptevo Therapeutics
07:05am, Wednesday, 24'th Mar 2021
An Assessment On Aptevo Therapeutics
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
08:00am, Monday, 11'th Jan 2021
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology the
Aptevo: Positive Early Stage Data Makes This Highly Interesting
01:52pm, Wednesday, 02'nd Dec 2020
Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer.
LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ -- Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-direct
Aptevo Therapeutics News: Why APVO Stock Is Falling 15% Today
10:02am, Wednesday, 04'th Nov 2020
Aptevo Therapeutics (APVO) news for Wednesday includes APVO stock taking a fall after a strong rally yesterday on clinical trial results. The post Aptevo Therapeutics News: Why APVO Stock Is Falling 1
The
Aptevo Therapeutics Reports Second Quarter 2020 Financial Results
01:00pm, Friday, 14'th Aug 2020
* Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Complete * Presents New Preclinical Data Showin
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust | | IT Business Net
03:11pm, Thursday, 06'th Aug 2020
Extends Cash Runway into Q3 2021 The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May De
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust
01:00pm, Thursday, 06'th Aug 2020
Extends Cash Runway into Q3 2021The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May Del
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones
01:00pm, Tuesday, 21'st Jul 2020
SEATTLE, WA / ACCESSWIRE / July 21, 2020 / Aptevo Therapeutics Inc.
$290,000.00 in Sales Expected for Aptevo Therapeutics Inc (NASDAQ:APVO) This Quarter
01:36am, Saturday, 18'th Jul 2020
Wall Street analysts expect that Aptevo Therapeutics Inc (NASDAQ:APVO) will post $290,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates f
Top Stocks To Short As Nasdaq Sets New Intraday Record
12:00am, Monday, 13'th Jul 2020
Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the major thr
